Current management of lymphangioleiomyomatosis

Current Opinion in Pulmonary Medicine

Volumn 17, Issue 5, 2011, Pages 374-378

  Taillé, Camille ^a   Borie, Raphaël ^a   Crestani, Bruno ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Chylothorax; doxycycline; lung cysts; lung transplantation; sirolimus

Indexed keywords

DOXYCYCLINE; RAPAMYCIN; VASCULOTROPIN D;

ABDOMINAL MASS; ANGIOMYOLIPOMA; CHRONIC RESPIRATORY FAILURE; CHYLOTHORAX; CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE; GENE MUTATION; HUMAN; HYPERLIPIDEMIA; LUNG CYST; LUNG FUNCTION; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; MUCOSA INFLAMMATION; PNEUMOTHORAX; QUALITY OF LIFE; RARE DISEASE; RASH; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT RESPONSE; TSC1 GENE; TSC2 GENE;

ANTI-BACTERIAL AGENTS; DOXYCYCLINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHANGIOLEIOMYOMATOSIS; QUALITY OF LIFE; SIROLIMUS; TREATMENT OUTCOME;

EID: 80051790221     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328349ac8c     Document Type: Review

References (31)

1. McCormack FX. Lymphangioleiomyomatosis: a clinical update. Chest 2008;133:507-516. (Pubitemid 351272412)
2. Smolarek TA, Wessner LL, McCormack FX, et al. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 1998;62:810-815. (Pubitemid 28194322)
3. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35:14-26. A recent evidence-based, consensus guidelines for the diagnosis, assessment and treatment of LAM.
4. Ikeda Y, Taveira-DaSilva AM, Pacheco-Rodriguez G, et al. Erythropoietindriven proliferation of cells with mutations in the tumor suppressor gene TSC2. Am J Physiol Lung Cell Mol Physiol 2011;300:L64-72.
5. Goncharova EA, Goncharov DA, Spaits M, et al. Abnormal growth of smooth muscle-like cells in lymphangioleiomyomatosis: role for tumor suppressor TSC2. Am J Respir Cell Mol Biol 2006;34:561-572.
6. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-151.
7. Davies DM, Johnson SR, Tattersfield AE, et al. Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis. N Engl J Med 2008;358:200-203.
8. Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res 2011;17:4071-4081. The trial demonstrates that sirolimus could reduce the size of angiomyolipoma in LAM. No effect was observed on lung function in this small series.
9. McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1595-1606. The first placebo controlled randomized trial with sirolimus for pulmonary LAM demonstrates lung function stabilization with treatment, and the need for long-term administration to maintain this effect.
10. Groetzner J, Kur F, Spelsberg F, et al. Airway anastomosis complications in de novo lung transplantation with sirolimus-based immunosuppression. J Heart Lung Transplant 2004;23:632-638. (Pubitemid 38595752)
11. Finlay GA, Malhowski AJ, Liu Y, et al. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity. Cancer Res 2007;67:9878-9886. (Pubitemid 47621236)
12. El-Chemaly S, Taveira-DaSilva A, Stylianou MP, et al. Statins in lymphangioleiomyomatosis: a word of caution. Eur Respir J 2009;34:513-514.
13. Herry I, Neukirch C, Debray MP, et al. Dramatic effect of sirolimus on renal angiomyolipomas in a patient with tuberous sclerosis complex. Eur J Intern Med 2007;18:76-77. (Pubitemid 46091655)
14. Taille C, Debray MP, Crestani B. Sirolimus treatment for pulmonary lymphangioleiomyomatosis. Ann Intern Med 2007;146:687-688. (Pubitemid 351650533)
15. Glassberg MK, Elliot SJ, Fritz J, et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab 2008;93:1625-1633. (Pubitemid 351656497)
16. Chang WY, Clements D, Johnson SR. Effect of doxycycline on proliferation, MMP production, and adhesion in LAM-related cells. Am J Physiol Lung Cell Mol Physiol 2010;299:L393-400.
17. Moir L, Ng H, Poniris M, et al. Doxycycline inhibits matrix metalloproteinase-2 secretion from TSC2-null mouse embryonic fibroblasts and lymphangioleiomyomatosis cells. Br J Pharmacol 2011. doi:10.1111/j.1476-5381. 2011. 01344.x. [Epub ahead of print].
18. Moses MA, Harper J, Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 2006;354:2621-2622. (Pubitemid 43882375)
19. Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 2009;135:1293-1300.
20. Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010;138:674-681. This prospective study provides evidence on the role of serum levels of VEGF-D to identify LAM among patients with other cystic lung diseases.
21. Cottin V, Lacronique J, Denis L, et al. Diagnostic value of serum VEGF-D in consecutive patients with lymphangioleiomyomatosis [abstract]. Am J Respir Crit Care Med 2011;183:A1636.
22. Shigemura N, Kawamura T, Minami M, et al. Successful factor XIII administration for persistent chylothorax after lung transplantation for lymphangioleiomyomatosis. Ann Thorac Surg 2009;88:1003-1006.
23. Almoosa KF, Ryu JH, Mendez J, et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006;129:1274-1281.
24. Noda M, Okada Y, Maeda S, et al. An experience with the modified total pleural covering technique in a patient with bilateral intractable pneumothorax secondary to lymphangioleiomyomatosis. Ann Thorac Cardiovasc Surg 2010;16:439-441.
25. Benden C, Rea F, Behr J, et al. Lung transplantation for lymphangioleiomyomatosis: the European experience. J Heart Lung Transplant 2009;28:1-7.
26. Reynaud-Gaubert M, Mornex JF, Mal H, et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation 2008;86:515-520.
27. Maurer JR, Ryu J, Beck G, et al. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry. J Heart Lung Transplant 2007;26:1293-1299. (Pubitemid 350256988)
28. Chen F, Omasa M, Kondo N, et al. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. Ann Thorac Surg 2009;87:e6-e7.
29. Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 2009;106:2635-2640.
30. Cohen MM, Freyer AM, Johnson SR. Pregnancy experiences among women with lymphangioleiomyomatosis. Respir Med 2009;103:766-772.
31. Yu J, Parkhitko AA, Henske EP. Mammalian target of rapamycin signaling and autophagy: roles in lymphangioleiomyomatosis therapy. Proc Am Thorac Soc 2010;7:48-53.